EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
Overall EXAS gets a fundamental rating of 3 out of 10. We evaluated EXAS against 571 industry peers in the Biotechnology industry. EXAS may be in some trouble as it scores bad on both profitability and health. EXAS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EXAS had negative earnings in the past year.
EXAS had a positive operating cash flow in the past year.
In the past 5 years EXAS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
EXAS has a Return On Assets of -3.17%. This is amongst the best in the industry. EXAS outperforms 90.65% of its industry peers.
EXAS has a Return On Equity of -6.67%. This is amongst the best in the industry. EXAS outperforms 92.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.17% | ||
| ROE | -6.67% | ||
| ROIC | N/A |
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 72.96%, EXAS belongs to the top of the industry, outperforming 84.30% of the companies in the same industry.
In the last couple of years the Gross Margin of EXAS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
EXAS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EXAS has more shares outstanding
The debt/assets ratio for EXAS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.35, we must say that EXAS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.35, EXAS is in the better half of the industry, outperforming 68.43% of the companies in the same industry.
The Debt to FCF ratio of EXAS is 48.81, which is on the high side as it means it would take EXAS, 48.81 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 48.81, EXAS belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
EXAS has a Debt/Equity ratio of 0.73. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
EXAS has a Debt to Equity ratio of 0.73. This is in the lower half of the industry: EXAS underperforms 76.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 48.81 | ||
| Altman-Z | 1.35 |
ROIC/WACCN/A
WACC9.46%
2.3 Liquidity
A Current Ratio of 2.12 indicates that EXAS has no problem at all paying its short term obligations.
EXAS's Current ratio of 2.12 is on the low side compared to the rest of the industry. EXAS is outperformed by 74.78% of its industry peers.
A Quick Ratio of 1.93 indicates that EXAS should not have too much problems paying its short term obligations.
The Quick ratio of EXAS (1.93) is worse than 75.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.42%, which is quite impressive.
Looking at the last year, EXAS shows a quite strong growth in Revenue. The Revenue has grown by 11.91% in the last year.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 40.63% on average per year.
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)11.91%
Revenue growth 3Y18.79%
Revenue growth 5Y40.63%
Sales Q2Q%12.78%
3.2 Future
The Earnings Per Share is expected to grow by 31.77% on average over the next years. This is a very strong growth
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.71% yearly.
EPS Next Y0.07%
EPS Next 2Y30.25%
EPS Next 3Y32.62%
EPS Next 5Y31.77%
Revenue Next Year10.59%
Revenue Next 2Y11.11%
Revenue Next 3Y11.17%
Revenue Next 5Y11.71%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXAS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
EXAS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.06% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 92.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 185.01 | ||
| EV/EBITDA | 1555.24 |
4.3 Compensation for Growth
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 32.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.25%
EPS Next 3Y32.62%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXACT SCIENCES CORP
NASDAQ:EXAS (11/22/2024, 8:00:02 PM)
After market: 52.5 -0.41 (-0.77%)52.91
-0.16 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.79B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.17% | ||
| ROE | -6.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.96% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y0.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.91%
Revenue growth 3Y18.79%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y